{"status": "Ok", "redirect_url": "https://www.businesswire.com/news/home/20260512064160/en/Definium-Therapeutics-Announces-First-Patient-Dosed-in-Ascend-the-Second-Phase-3-Pivotal-Study-of-DT120-ODT-in-Major-Depressive-Disorder", "message": "News view counter 718934 successfully enlarged"}